Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEF 14A
Definitive proxy
19 Apr 24
8-K
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
12 Mar 24
S-8
Registration of securities for employees
20 Feb 24
10-K
2023 FY
Annual report
20 Feb 24
8-K
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023
20 Feb 24
8-K
Other Events
23 Jan 24
8-K
Entry into a Material Definitive Agreement
19 Jan 24
424B5
Prospectus supplement for primary offering
19 Jan 24
8-K
Other Events
16 Jan 24
8-K
Other Events
12 Jan 24
8-K
IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder Cancer
4 Dec 23
8-K
Entry into a Material Definitive Agreement
17 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
IDEAYA Biosciences, Inc. Reports Third Quarter 2023
7 Nov 23
8-K
Other Events
27 Oct 23
424B5
Prospectus supplement for primary offering
25 Oct 23
424B5
Prospectus supplement for primary offering
24 Oct 23
8-K
Results of Operations and Financial Condition
24 Oct 23
8-K
Other Events
23 Oct 23
8-K
Departure of Directors or Certain Officers
26 Sep 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
IDEAYA Biosciences, Inc. Reports Second Quarter 2023
10 Aug 23
8-K
Departure of Directors or Certain Officers
3 Jul 23
8-K
Entry into a Material Definitive Agreement
30 Jun 23
424B5
Prospectus supplement for primary offering
26 Jun 23
S-3ASR
Automatic shelf registration
26 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
8-K
Entry into a Material Definitive Agreement
6 Jun 23
8-K
IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer
16 May 23
ARS
2022 FY
Annual report to shareholders
12 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
IDEAYA Biosciences, Inc. Reports First Quarter 2023 Financial Results
9 May 23
8-K
Other Events
27 Apr 23
424B5
Prospectus supplement for primary offering
25 Apr 23
424B5
Prospectus supplement for primary offering
24 Apr 23
8-K
Results of Operations and Financial Condition
24 Apr 23
8-K
Other Events
24 Apr 23
DEF 14A
Definitive proxy
14 Apr 23
8-K
Other Events
10 Mar 23
Latest ownership filings
4
Yujiro S Hata
4 Mar 24
4
Briseno Andres Ruiz
4 Mar 24
4
Darrin Beaupre
4 Mar 24
4
MICHAEL ANTHONY WHITE
4 Mar 24
4
Jason Throne
4 Mar 24
SC 13G
JANUS HENDERSON GROUP PLC
14 Feb 24
SC 13G
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
Avidity Partners Management LP
14 Feb 24
SC 13G/A
Logos Global Management LP
13 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
4
Briseno Andres Ruiz
13 Feb 24
4
Yujiro S Hata
12 Feb 24
SC 13G
FMR LLC
12 Feb 24
144
Notice of proposed sale of securities
9 Feb 24
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
4
Yujiro S Hata
5 Feb 24
SC 13G/A
CANAAN X L.P.
1 Feb 24
144
Notice of proposed sale of securities
1 Feb 24
SC 13G/A
BlackRock Inc.
25 Jan 24
4
Briseno Andres Ruiz
24 Jan 24
SC 13G/A
FEDERATED HERMES, INC.
18 Jan 24
4
Briseno Andres Ruiz
17 Jan 24
4
Yujiro S Hata
17 Jan 24
144
Notice of proposed sale of securities
12 Jan 24
144
Notice of proposed sale of securities
12 Jan 24
144
Notice of proposed sale of securities
27 Dec 23
4
Jason Throne
19 Dec 23
4
Yujiro S Hata
19 Dec 23
4
Briseno Andres Ruiz
18 Dec 23
144
Notice of proposed sale of securities
15 Dec 23
144
Notice of proposed sale of securities
15 Dec 23
144
Notice of proposed sale of securities
14 Dec 23
144
Notice of proposed sale of securities
11 Dec 23
144
Notice of proposed sale of securities
4 Dec 23
144
Notice of proposed sale of securities
28 Nov 23
144
Notice of proposed sale of securities
27 Nov 23
4
Jason Throne
7 Nov 23
4
Jason Throne
14 Sep 23
4
Jason Throne
6 Sep 23